Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sutro Biopharma Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 7 distinct art units, so prosecution is distributed broadly across both examining personnel and technical assignments.
HUYNH, PHUONG N is the busiest examiner, with 2 pending matters. That assignment warrants direct attention, but the remaining matters require separate examiner-specific analysis because the portfolio does not center on a single art unit.
The breadth of the assignments favors a coordinated claim architecture and consistent disclosure positions across responses. At the same time, counsel should avoid treating the matters as interchangeable, since examiner practice and art-unit context may shape the most effective amendment and argument choices.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 3 (38%) |
| Double-patenting + other | 3 (38%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 2 | 65.8% | +53.6% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18203348 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | HELLMAN, KRISTINA M | 26d overdue |
| 16991607 | EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION | RYAN, DOUGLAS CHARLES | 18d overdue |
| 17727395 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | 2d overdue |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | PERSONS, JENNA L | 6d |
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | KAUFMAN, CLAIRE M | 15d |
| 18231204 | SPRAY DRIED EXTRACT | REGLAS, GEORGIANA C | 22d |
| 18426426 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | — |
| 18215093 | BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1674 | 1 |
| 1651 | 1 |
| 1693 | 1 |
| 1654 | 1 |
| 1635 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | KAUFMAN, CLAIRE M | 1674 | §112 | Non-Final OA | 15d | Pending | Apr 17, 2024 |
| 18426426 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Jan 30, 2024 |
| 18231204 | SPRAY DRIED EXTRACT | REGLAS, GEORGIANA C | 1651 | §103 | Final Rejection | 22d | Pending | Aug 07, 2023 |
| 18215093 | BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18203348 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112 | Non-Final OA | 26d overdue | Pending | May 30, 2023 |
| 17727395 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | 1641 | §112Other | Final Rejection | 2d overdue | Pending | Apr 22, 2022 |
| 16991607 | EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION | RYAN, DOUGLAS CHARLES | 1635 | §103§112DP | Final Rejection | 18d overdue | Pending | Aug 12, 2020 |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | PERSONS, JENNA L | 1637 | §103DP | Final Rejection | 6d | Pending | Apr 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSutro Biopharma Inc. has 8 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Phuong N Huynh has the most, with 2 of Sutro Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
